Payment overview · 2025
General Payments
$695.48
34 reported records · 18 companies
Healthcare provider profile · identity verified
Robert J Reichling, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LENOIR, NC · NPI 1144268616
Verified facts
What the public records show
CMS Open Payments records show Robert J Reichling, M.D. received $695.48 in general payments during 2025 across 34 reported records.
Viatris Specialty LLC accounted for 14.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 286 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $100.59 | 14.5% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $97.17 | 14.0% | 5 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $86.30 | 12.4% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $44.93 | 6.5% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $42.20 | 6.1% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $39.03 | 5.6% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.57 | 5.3% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $30.45 | 4.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.39 | 4.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.09 | 3.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.26 | 3.8% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $25.83 | 3.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.36 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.51 | 3.1% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.37 | 2.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.75 | 2.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.41 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.27 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $695.48 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $100.59 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $97.17 | 5 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $86.30 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $44.93 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $42.96 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $42.20 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $39.03 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $36.57 | 2 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $30.45 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.26 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.26 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
151 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
286 | 59 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 658 | 163 |
| Atorvastatin Calcium | Atorvastatin Calcium | 624 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 599 | 162 |
| Omeprazole | Omeprazole | 462 | 121 |
| Losartan Potassium | Losartan Potassium | 445 | 120 |
| Gabapentin | Gabapentin | 444 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 406 | 122 |
| Furosemide | Furosemide | 388 | 100 |
| Metformin Hcl | Metformin Hcl | 365 | 104 |
| Lisinopril | Lisinopril | 327 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 323 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 310 | 72 |
| Eliquis | Apixaban | 286 | 59 |
| Potassium Chloride | Potassium Chloride | 281 | 72 |
| Mounjaro | Tirzepatide | 271 | 44 |
| Tramadol Hcl | Tramadol Hcl | 270 | 54 |
| Glimepiride | Glimepiride | 254 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 67 |
| Simvastatin | Simvastatin | 233 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 226 | 64 |
| Alprazolam | Alprazolam | 222 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 221 | 68 |
| Pravastatin Sodium | Pravastatin Sodium | 218 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 200 | 46 |
| Carvedilol | Carvedilol | 180 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 165 | 27 |
| Lorazepam | Lorazepam | 162 | 37 |
| Allopurinol | Allopurinol | 160 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 44 |
| Ozempic | Semaglutide | 151 | 30 |
| Famotidine | Famotidine | 147 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 140 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 39 |
| Meloxicam | Meloxicam | 127 | 44 |
| Sertraline Hcl | Sertraline Hcl | 127 | 36 |
| Trazodone Hcl | Trazodone Hcl | 121 | 41 |
| Ezetimibe | Ezetimibe | 115 | 33 |
| Jardiance | Empagliflozin | 106 | 21 |
| Montelukast Sodium | Montelukast Sodium | 106 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 105 | 66 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 101 | 23 |
| Prednisone | Prednisone | 101 | 56 |
| Doxycycline Hyclate | Doxycycline Hyclate | 96 | 82 |
| Valsartan | Valsartan | 96 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 28 |
| Clonazepam | Clonazepam | 93 | 16 |
| Irbesartan | Irbesartan | 90 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 85 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 18 |
| Spironolactone | Spironolactone | 81 | 18 |
| Donepezil Hcl | Donepezil Hcl | 79 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 71 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 16 |
| Estradiol | Estradiol | 66 | 17 |
| Warfarin Sodium | Warfarin Sodium | 65 | 11 |
| Xarelto | Rivaroxaban | 65 | 13 |
| Mirtazapine | Mirtazapine | 63 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 22 |
| Entresto | Sacubitril/Valsartan | 60 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 60 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 19 |
| Nystatin | Nystatin | 59 | 26 |
| Farxiga | Dapagliflozin Propanediol | 58 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 11 |
| Bupropion Xl | Bupropion Hcl | 56 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 56 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 19 |
| Buspirone Hcl | Buspirone Hcl | 53 | 12 |
| Metformin Hcl Er | Metformin Hcl | 53 | 15 |
| Promethazine Hcl | Promethazine Hcl | 53 | 14 |
| Synthroid | Levothyroxine Sodium | 53 | 16 |
| Temazepam | Temazepam | 53 | 13 |
| Chlorthalidone | Chlorthalidone | 52 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 41 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 12 |
| Azelastine Hcl | Azelastine Hcl | 49 | 17 |
| Cephalexin | Cephalexin | 49 | 30 |
| Meclizine Hcl | Meclizine Hcl | 49 | 19 |
| Celecoxib | Celecoxib | 48 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 14 |
| Atenolol | Atenolol | 46 | 14 |
| Cefdinir | Cefdinir | 46 | 40 |
| Clonidine Hcl | Clonidine Hcl | 46 | suppressed |
| Pregabalin | Pregabalin | 46 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 15 |
| Azithromycin | Azithromycin | 44 | 37 |
| Diazepam | Diazepam | 44 | 12 |
| Topiramate | Topiramate | 44 | suppressed |
| Lovastatin | Lovastatin | 43 | 11 |
| Benazepril Hcl | Benazepril Hcl | 42 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 11 |
| Baclofen | Baclofen | 39 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 39 | 12 |
| Glipizide | Glipizide | 38 | 11 |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 35 |
| Valacyclovir | Valacyclovir Hcl | 35 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Klor-Con M20 | Potassium Chloride | 32 | 15 |
| Labetalol Hcl | Labetalol Hcl | 30 | 11 |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | 13 |
| Hydrocortisone | Hydrocortisone | 27 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Klor-Con M10 | Potassium Chloride | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Clonidine | Clonidine | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 13 |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Colchicine | Colchicine | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Crestor | Rosuvastatin Calcium | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $695.48 · 34 records | Viatris Specialty LLC | Arikayce, BREZTRI, Brinsupri, Cologuard Collection Kit, DUPIXENT, ETERNA, FARXIGA, KEYTRUDA, Korlym, NURTEC ODT, Ohtuvayre, Omnipod, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, QULIPTA, TONMYA, Tyvaso, UBRELVY, Wegovy, YUPELRI, ZAVZPRET, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error